Novartis made headlines when it won FDA approval for Kymriah, the first CAR-T cell therapy to reach the market. Last week, two years after it was commercialized, the company presented post-marketing data showing that its efficacy is consistent with what was shown in clinical trials, and the safety profile appears even better, according to Novartis's presentation at the annual American Society of Hematology (ASH) annual conference. With the wave of CAR-T and other cell therapies being investigated in clinical trials, Yourway has invested in its temperature-controlled logistics capabilities to support the special requirements of these trials.